Skip to content
Disclosery

Affinity Asset Advisors, LLC

Follow

13F filer, CIK 1773195, NEW YORK, NY

Affinity Asset Advisors, LLC reported $1,936,321,061 across 105 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-14. Its ten largest share positions make up 42.4% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001315863-26-000411

Period
2026-03-31
Reported value
$1.94B
Holdings
105
Top 10 weight
42.4%
New
29
Sold out
19

Largest buys vs the previous quarter

SecurityShares changeApprox. value
CNTAadded+799,448$31.8M
ROIVadded+1,100,000$30.5M
ANABadded+495,308$27.5M
XENEadded+425,000$24.7M
ERASadded+1,450,000$23.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
VTYXexited-6,484,558-$58.6M
ACLXreduced-160,961-$18.5M
CGEMreduced-1,150,846-$16.4M
ORKAreduced-302,669-$14.8M
BBIOreduced-170,000-$12.6M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001315863-26-000411, largest first. % of portfolio is the value over $1,705,088,311, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
APGEAPOGEE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 664,198 shares; 2024Q4: 931,728 shares; 2025Q1: 1,151,199 shares; 2025Q2: 691,899 shares; 2025Q3: 1,173,426 shares; 2025Q4: 1,234,926 shares; 2026Q1: 1,284,926 shares 1,284,926$108M6.34%+50,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,144,021 shares; 2024Q4: 1,161,237 shares; 2025Q1: 1,328,175 shares; 2025Q2: 1,100,000 shares; 2025Q3: 1,400,000 shares; 2025Q4: 1,250,000 shares; 2026Q1: 1,675,000 shares 1,675,000$97.4M5.71%+425,000Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,499,431 shares; 2024Q4: 2,499,431 shares; 2025Q1: 3,341,519 shares; 2025Q2: 4,085,787 shares; 2025Q3: 4,285,787 shares; 2025Q4: 3,900,000 shares; 2026Q1: 5,350,000 shares 5,350,000$86.6M5.08%+1,450,000Timeline
INSMINSMED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 50,000 shares; 2024Q4: 50,000 shares; 2025Q1: 140,000 shares; 2025Q2: 475,000 shares; 2025Q3: 450,000 shares; 2025Q4: 450,000 shares; 2026Q1: 480,000 shares 480,000$78.5M4.6%+30,000Timeline
ROIVROIVANT SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 201,587 shares; 2024Q4: not reported; 2025Q1: 150,000 shares; 2025Q2: 400,000 shares; 2025Q3: 800,000 shares; 2025Q4: 1,700,000 shares; 2026Q1: 2,800,000 shares 2,800,000$77.6M4.55%+1,100,000Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 498,420 shares; 2024Q4: 824,328 shares; 2025Q1: 481,678 shares; 2025Q2: 606,678 shares; 2025Q3: 1,419,299 shares; 2025Q4: 1,432,591 shares; 2026Q1: 1,279,134 shares 1,279,134$64.5M3.78%-153,457Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 965,612 shares; 2024Q4: 1,095,924 shares; 2025Q1: 1,546,662 shares; 2025Q2: 900,162 shares; 2025Q3: 1,107,162 shares; 2025Q4: 600,552 shares; 2026Q1: 1,400,000 shares 1,400,000$55.6M3.26%+799,448Timeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 185,000 shares; 2026Q1: 170,000 shares 170,000$54.8M3.21%-15,000Timeline
ANABANAPTYSBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 444,692 shares; 2026Q1: 940,000 shares 940,000$52.1M3.06%+495,308Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,000,000 shares; 2024Q4: 1,100,000 shares; 2025Q1: 1,000,000 shares; 2025Q2: 1,000,000 shares; 2025Q3: 1,250,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,350,000 shares 1,350,000$47.7M2.8%+350,000Timeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 350,000 shares; 2025Q4: 800,000 shares; 2026Q1: 700,483 shares 700,483$46.2M2.71%-99,517Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 200,000 shares; 2025Q2: 100,000 shares; 2025Q3: 360,000 shares; 2025Q4: 505,000 shares; 2026Q1: 405,000 shares 405,000$45.1M2.64%-100,000Timeline
TEVATEVA PHARMACEUTICAL INDS LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,400,000 shares; 2024Q4: 1,400,000 shares; 2025Q1: 1,400,000 shares; 2025Q2: 1,400,000 shares; 2025Q3: 1,400,000 shares; 2025Q4: 1,400,000 shares; 2026Q1: 1,400,000 shares 1,400,000$42.2M2.47%0Timeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 400,000 shares; 2024Q4: 425,000 shares; 2025Q1: 530,000 shares; 2025Q2: 495,000 shares; 2025Q3: 500,000 shares; 2025Q4: 523,725 shares; 2026Q1: 362,764 shares 362,764$41.7M2.44%-160,961Timeline
NUVLNUVALENT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 337,500 shares; 2024Q4: 285,000 shares; 2025Q1: 460,000 shares; 2025Q2: 415,000 shares; 2025Q3: 384,417 shares; 2025Q4: 322,633 shares; 2026Q1: 300,000 shares 300,000$30.7M1.8%-22,633Timeline
TERNTERNS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 600,000 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 550,000 shares; 2026Q1: 562,631 shares 562,631$29.7M1.74%+12,631Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 262,100 shares; 2025Q4: 115,000 shares; 2026Q1: 350,000 shares 350,000$29.4M1.72%+235,000Timeline
LXEOLEXEO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,480,881 shares; 2025Q2: 3,589,355 shares; 2025Q3: 3,870,527 shares; 2025Q4: 3,200,000 shares; 2026Q1: 5,050,211 shares 5,050,211$29M1.7%+1,850,211Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 350,000 shares; 2026Q1: 750,000 shares 750,000$28.9M1.69%+400,000Timeline
MDGLMADRIGAL PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 100,000 shares; 2024Q4: 82,500 shares; 2025Q1: 80,000 shares; 2025Q2: 80,000 shares; 2025Q3: 115,000 shares; 2025Q4: 31,131 shares; 2026Q1: 55,000 shares 55,000$28.8M1.69%+23,869Timeline
STROSUTRO BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 748,382 shares; 2026Q1: 1,069,519 shares 1,069,519$26.6M1.56%+321,137Timeline
FBRXFORTE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 989,490 shares; 2026Q1: 1,011,890 shares 1,011,890$26.2M1.54%+22,400Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 349,836 shares; 2024Q4: 368,698 shares; 2025Q1: 545,362 shares; 2025Q2: 603,479 shares; 2025Q3: 959,180 shares; 2025Q4: 802,342 shares; 2026Q1: 499,673 shares 499,673$24.5M1.44%-302,669Timeline
TRVITREVI THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,250,000 shares; 2025Q2: 2,534,058 shares; 2025Q3: 2,800,000 shares; 2025Q4: 2,150,172 shares; 2026Q1: 2,000,172 shares 2,000,172$23.9M1.4%-150,000Timeline
OVIDOVID THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 667,516 shares; 2025Q2: 667,516 shares; 2025Q3: 2,650,000 shares; 2025Q4: 7,150,000 shares; 2026Q1: 10,636,318 shares 10,636,318$23.6M1.38%+3,486,318Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 400,000 shares; 2025Q3: 400,000 shares; 2025Q4: not reported; 2026Q1: 586,904 shares 586,904$23M1.35%newTimeline
ASNDASCENDIS PHARMA A/SQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 30,000 shares; 2026Q1: 95,000 shares 95,000$21.7M1.27%+65,000Timeline
MLYSMINERALYS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 350,000 shares; 2024Q4: 350,000 shares; 2025Q1: 1,100,000 shares; 2025Q2: 900,000 shares; 2025Q3: 750,000 shares; 2025Q4: 730,000 shares; 2026Q1: 750,000 shares 750,000$20.3M1.19%+20,000Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 45,000 shares; 2024Q4: 550,765 shares; 2025Q1: 657,154 shares; 2025Q2: 607,872 shares; 2025Q3: 1,006,217 shares; 2025Q4: 1,051,054 shares; 2026Q1: 1,340,840 shares 1,340,840$20M1.17%+289,786Timeline
PTGXPROTAGONIST THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 130,000 shares; 2025Q1: 400,000 shares; 2025Q2: 440,000 shares; 2025Q3: 220,600 shares; 2025Q4: 172,125 shares; 2026Q1: 172,125 shares 172,125$18.1M1.06%0Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 125,000 shares; 2024Q4: 9,992 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 300,000 shares; 2025Q4: 350,000 shares; 2026Q1: 500,000 shares 500,000$15.9M0.93%+150,000Timeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 223,335 shares; 2024Q4: 223,335 shares; 2025Q1: 223,335 shares; 2025Q2: 223,335 shares; 2025Q3: 1,274,351 shares; 2025Q4: 1,813,671 shares; 2026Q1: 2,564,303 shares 2,564,303$15.3M0.89%+750,632Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 860,399 shares; 2024Q4: 940,083 shares; 2025Q1: 810,669 shares; 2025Q2: 967,620 shares; 2025Q3: 967,620 shares; 2025Q4: 967,620 shares; 2026Q1: 967,620 shares 967,620$15M0.88%0Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 700,000 shares; 2024Q4: 410,586 shares; 2025Q1: not reported; 2025Q2: 500,000 shares; 2025Q3: 1,500,000 shares; 2025Q4: 2,797,153 shares; 2026Q1: 2,512,153 shares 2,512,153$13.7M0.8%-285,000Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 500,000 shares; 2024Q4: 1,300,000 shares; 2025Q1: 2,224,196 shares; 2025Q2: 1,050,000 shares; 2025Q3: 300,000 shares; 2025Q4: 300,000 shares; 2026Q1: 3,164,582 shares 3,164,582$13.2M0.77%+2,864,582Timeline
HLXCHELIX ACQUISITION CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,250,000 shares 1,250,000$12.7M0.74%newTimeline
ARWRARROWHEAD PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 325,000 shares; 2024Q4: 300,000 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 70,000 shares; 2026Q1: 200,000 shares 200,000$12.5M0.74%+130,000Timeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 450,000 shares 450,000$11.7M0.68%newTimeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 300,000 shares; 2025Q4: 300,000 shares; 2026Q1: 1,589,005 shares 1,589,005$11.5M0.67%+1,289,005Timeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares 500,000$11.2M0.66%newTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 300,000 shares; 2024Q4: 200,000 shares; 2025Q1: 300,000 shares; 2025Q2: 150,000 shares; 2025Q3: 65,000 shares; 2025Q4: 320,000 shares; 2026Q1: 150,000 shares 150,000$11.1M0.65%-170,000Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 263,817 shares; 2024Q4: 263,817 shares; 2025Q1: 263,817 shares; 2025Q2: 263,817 shares; 2025Q3: 263,817 shares; 2025Q4: 1,932,106 shares; 2026Q1: 781,260 shares 781,260$11.1M0.65%-1,150,846Timeline
BLTEBELITE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 20,000 shares; 2026Q1: 65,000 shares 65,000$10.4M0.61%+45,000Timeline
WVEWAVE LIFE SCIENCES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,400,000 shares; 2024Q4: 1,500,000 shares; 2025Q1: 1,825,000 shares; 2025Q2: 2,000,308 shares; 2025Q3: 2,100,000 shares; 2025Q4: 2,700,000 shares; 2026Q1: 1,401,727 shares 1,401,727$10.2M0.6%-1,298,273Timeline
VERAVERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 435,000 shares; 2024Q4: 425,000 shares; 2025Q1: 355,143 shares; 2025Q2: 545,000 shares; 2025Q3: 303,330 shares; 2025Q4: 250,000 shares; 2026Q1: 250,000 shares 250,000$10.1M0.59%0Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 257,512 shares 257,512$9.86M0.58%newTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 100,000 shares 100,000$9.72M0.57%0Timeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 65,317 shares; 2025Q3: 65,317 shares; 2025Q4: 714,956 shares; 2026Q1: 639,956 shares 639,956$8.99M0.53%-75,000Timeline
TVTXTRAVERE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 200,000 shares; 2025Q1: 1,070,000 shares; 2025Q2: 970,000 shares; 2025Q3: 500,000 shares; 2025Q4: 300,000 shares; 2026Q1: 300,000 shares 300,000$8.91M0.52%0Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 472,390 shares; 2024Q4: 425,000 shares; 2025Q1: 325,000 shares; 2025Q2: 275,000 shares; 2025Q3: 275,000 shares; 2025Q4: 275,000 shares; 2026Q1: 275,000 shares 275,000$8.8M0.52%0Timeline
KRROKORRO BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 706,904 shares 706,904$8M0.47%newTimeline
CRSPCRISPR THERAPEUTICS AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 150,000 shares 150,000$7.14M0.42%newTimeline
SGPSPYGLASS PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 250,000 shares 250,000$6.48M0.38%newTimeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 300,512 shares; 2024Q4: 850,512 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 200,000 shares; 2025Q4: 200,000 shares; 2026Q1: 1,108,483 shares 1,108,483$6.13M0.36%+908,483Timeline
IBIOIBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 2,057,200 shares; 2026Q1: 3,107,200 shares 3,107,200$5.9M0.35%+1,050,000Timeline
ESTAESTABLISHMENT LABS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 290,447 shares; 2024Q4: 279,445 shares; 2025Q1: 280,000 shares; 2025Q2: 334,863 shares; 2025Q3: 310,000 shares; 2025Q4: 200,000 shares; 2026Q1: 100,000 shares 100,000$5.68M0.33%-100,000Timeline
AVRANTERIS TECHNOLOGIES GLOBALQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 300,000 shares; 2025Q1: 390,000 shares; 2025Q2: 425,000 shares; 2025Q3: 450,000 shares; 2025Q4: 486,684 shares; 2026Q1: 912,397 shares 912,397$5.06M0.3%+425,713Timeline
NEWAMSTERDAM PHARMA COMPANYNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 212,974 shares; 2024Q4: 237,935 shares; 2025Q1: 241,957 shares; 2025Q2: 245,000 shares; 2025Q3: 245,000 shares; 2025Q4: 245,000 shares; 2026Q1: 245,000 shares 245,000$4.91M0.29%0
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 525,000 shares; 2024Q4: 159,614 shares; 2025Q1: 390,000 shares; 2025Q2: 390,000 shares; 2025Q3: 250,000 shares; 2025Q4: 250,000 shares; 2026Q1: 250,000 shares 250,000$4.89M0.29%0Timeline
CLYMCLIMB BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,500,000 shares; 2024Q4: 500,000 shares; 2025Q1: 1,500,000 shares; 2025Q2: 1,500,000 shares; 2025Q3: 1,300,000 shares; 2025Q4: 1,300,000 shares; 2026Q1: 700,000 shares 700,000$4.79M0.28%-600,000Timeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,700,000 shares; 2024Q4: 1,575,000 shares; 2025Q1: 1,700,000 shares; 2025Q2: 2,200,000 shares; 2025Q3: 2,100,000 shares; 2025Q4: 2,351,144 shares; 2026Q1: 1,547,641 shares 1,547,641$4.72M0.28%-803,503Timeline
SGMTSAGIMET BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 350,000 shares; 2025Q4: 1,148,245 shares; 2026Q1: 868,020 shares 868,020$4.54M0.27%-280,225Timeline
MBXMBX BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 175,000 shares; 2025Q2: not reported; 2025Q3: 165,000 shares; 2025Q4: 250,000 shares; 2026Q1: 150,000 shares 150,000$4.48M0.26%-100,000Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 200,000 shares; 2025Q3: 3,000,000 shares; 2025Q4: 3,300,000 shares; 2026Q1: 1,000,000 shares 1,000,000$4.47M0.26%-2,300,000Timeline
MANEVERADERMICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 70,000 shares 70,000$4.42M0.26%newTimeline
GENBGENERATE BIOMEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 350,000 shares 350,000$4.38M0.26%newTimeline
ENGNENGENE HOLDINGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 77,000 shares; 2025Q3: 77,000 shares; 2025Q4: 643,370 shares; 2026Q1: 610,370 shares 610,370$4.16M0.24%-33,000Timeline
AVBPARRIVENT BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 150,000 shares; 2026Q1: 175,000 shares 175,000$4.04M0.24%+25,000Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 400,000 shares 400,000$3.98M0.23%newTimeline
PRQRPROQR THRAPEUTICS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 2,825,000 shares; 2025Q1: 3,284,512 shares; 2025Q2: 3,499,512 shares; 2025Q3: 3,600,000 shares; 2025Q4: 2,454,278 shares; 2026Q1: 2,454,278 shares 2,454,278$3.98M0.23%0Timeline
VRCAVERRICA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 707,338 shares; 2026Q1: 707,338 shares 707,338$3.74M0.22%0Timeline
DTILPRECISION BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 597,946 shares 597,946$3.29M0.19%newTimeline
KPTIKARYOPHARM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 889,575 shares; 2026Q1: 500,000 shares 500,000$2.79M0.16%-389,575Timeline
SLGLSOL-GEL TECHNOLOGIES LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 35,000 shares 35,000$2.77M0.16%newTimeline
CRNXCRINETICS PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 400,000 shares; 2024Q4: 460,000 shares; 2025Q1: 152,252 shares; 2025Q2: 152,252 shares; 2025Q3: 75,000 shares; 2025Q4: 75,000 shares; 2026Q1: 75,000 shares 75,000$2.72M0.16%0Timeline
OACCUOAKTREE ACQUISITION CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 250,000 shares; 2025Q1: 250,000 shares; 2025Q2: 250,000 shares; 2025Q3: 250,000 shares; 2025Q4: 250,000 shares; 2026Q1: 250,000 shares 250,000$2.66M0.16%0Timeline
NXTCNEXTCURE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 191,882 shares; 2025Q4: 247,294 shares; 2026Q1: 241,826 shares 241,826$2.58M0.15%-5,468Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 225,000 shares; 2024Q4: 100,000 shares; 2025Q1: 430,000 shares; 2025Q2: not reported; 2025Q3: 300,000 shares; 2025Q4: 200,000 shares; 2026Q1: 100,000 shares 100,000$2.48M0.15%-100,000Timeline
EQEQUILLIUM INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,226,310 shares 1,226,310$2.45M0.14%newTimeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 575,000 shares 575,000$2.2M0.13%newTimeline
CORTCORCEPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 50,000 shares 50,000$2.02M0.12%newTimeline
OBIOORCHESTRA BIOMED HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 727,272 shares; 2025Q4: 572,804 shares; 2026Q1: 402,550 shares 402,550$1.71M0.1%-170,254Timeline
KZRKEZAR LIFE SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 142,316 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 229,076 shares; 2026Q1: 229,076 shares 229,076$1.7M0.1%0Timeline
MGNXMACROGENICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 484,308 shares; 2026Q1: 500,000 shares 500,000$1.45M0.08%+15,692Timeline
ANLADLAI NORTYE GROUP LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 164,748 shares 164,748$1.14M0.07%newTimeline
ALECALECTOR INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares 500,000$1.07M0.06%newTimeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 144,159 shares; 2025Q1: 394,159 shares; 2025Q2: 347,990 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 240,963 shares 240,963$998K0.06%newTimeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 100,000 shares 100,000$915K0.05%newTimeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 145,000 shares; 2026Q1: 145,000 shares 145,000$599K0.04%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 27,777 shares; 2024Q4: 27,777 shares; 2025Q1: 27,777 shares; 2025Q2: 27,777 shares; 2025Q3: 27,777 shares; 2025Q4: 27,777 shares; 2026Q1: 27,777 shares 27,777$178K0.01%0Timeline
ADGMADAGIO MED HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 213,235 shares; 2024Q4: 213,235 shares; 2025Q1: 213,235 shares; 2025Q2: 80,000 shares; 2025Q3: 80,000 shares; 2025Q4: 80,000 shares; 2026Q1: 80,000 shares 80,000$92K0.01%0Timeline
RCKTWROCKET PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 75,000 shares; 2024Q4: 75,000 shares; 2025Q1: 75,000 shares; 2025Q2: 75,000 shares; 2025Q3: 75,000 shares; 2025Q4: 75,000 shares; 2026Q1: 75,000 shares 75,000$1.18K<0.01%0Timeline

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
SPYSTATE STR SPDR S&P 500 ETF T SHSput200,000$130Mnew
MRNAMODERNA INC COMcall800,000$40.6Mnew
BMYBRISTOL-MYERS SQUIBB CO COMcall300,000$18.2Mnew
RVMDREVOLUTION MEDICINES INC Stockput100,000$9.72Mnew
IBRXIMMUNITYBIO INC COMput1,250,000$9.59Mnew
NVONOVO-NORDISK A S ADRcall175,000$6.43Mnew
QUREUNIQURE NV SHScall300,000$4.91M-500,000
DNTHDIANTHUS THERAPEUTICS INC COMcall50,000$4.2Mnew
CGONCG ONCOLOGY INC COMMON STOCKcall60,000$4.06Mnew
CELCCELCUITY INC COMcall30,000$3.42Mnew

Principal amounts

Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).

SecurityTypeAmountValueChange
OMEROS CORPOMEROS CORP NOTE 9.500% 6/1principal6,525,000$13.2M0
COGENT BIOSCIENCES INCCOGENT BIOSCIENCES INC NOTE 1.625%11/1principal7,000,000$8.59M+6,000,000
CELCUITY INCCELCUITY INC NOTE 2.750% 8/0principal3,000,000$7.31M0

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
XBISPDR SERIES TRUST1,500,000$183Mput
IBBISHARES TR400,000$67.5Mcall
VTYXVENTYX BIOSCIENCES INC6,484,558$58.6Mshares
AMGNAMGEN INC135,000$44.2Mcall
XLVSELECT SECTOR SPDR TR250,000$38.7Mcall
TRAVERE THERAPEUTICS INCTRAVERE THERAPEUTICS INC7,000,000$9.99Mprincipal
TNGXTANGO THERAPEUTICS INC1,000,000$8.86Mshares
RCUSARCUS BIOSCIENCES INC300,000$7.15Mshares
SMMTSUMMIT THERAPEUTICS INC350,000$6.12Mput
AVADEL PHARMACEUTICALSAVADEL PHARMACEUTICALS250,000$5.39Mshares
AMGNAMGEN INC10,000$3.27Mshares
MERSANA THERAPEUTICS INCMERSANA THERAPEUTICS INC100,000$2.89Mshares
ABUSARBUTUS BIOPHARMA CORP521,900$2.51Mcall
GERNGERON CORP1,500,000$1.98Mshares
RAREULTRAGENYX PHARMACEUTICAL IN75,000$1.73Mshares
LENZLENZ THERAPEUTICS INC100,000$1.6Mput
QUREUNIQURE NV50,000$1.2Mshares
FRNMPERCEPTIVE CAP SOLUTIONS COR50,000$652Kshares
FBRXFORTE BIOSCIENCES INC22,400$611Kcall

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001315863-26-000411 base2026-05-14acceptance time not in the bulk data set